Abstract 465P
Background
Afatinib has demonstrated efficacy and safety in pts with EGFRm+ NSCLC. We report a biomarker analysis of EGFR TKI-naïve pts with EGFRm+ NSCLC treated with afatinib in a Phase IIIb study. The analysis explored the effect of tumor mutation status on patient outcomes.
Methods
Pts with EGFR TKI-naïve locally advanced/metastatic EGFRm+ NSCLC received 40 mg/day afatinib. Primary endpoint was incidence of serious adverse events (SAEs). Secondary endpoints included drug-related AEs (DRAEs). Progression-free survival (PFS) was a further endpoint. For biomarker analysis, DNA was extracted from peripheral blood samples and analyzed using an amplification refractory mutation system. Samples taken at baseline and regular intervals were analyzed for EGFR mutations; specified non-EGFR mutations were identified at baseline.
Results
This analysis included 64 Chinese pts (female 70%; mean age 57 years; EGFR mutations: L858R 50%; Del19 42%). All pts had ≥1 DRAE, most commonly (all grades/≥3) diarrhea (98/14%) and rash/acne (grouped term; 81/8%). 15 pts (23%) had ≥1 SAE; 6 (9.4%) had drug-related SAEs. 58 pts (90.6%) showed disease control; including 39 (60.9%) with an objective response. At baseline, 19/42 pts analyzed (45%) had additional non-EGFR mutations; 17 progressed, 2 died. Median PFS was 8 months (mo), vs 12 mo for pts with EGFR-only mutations (HR 1.72; 95% CI 0.88, 3.36; p = 0.1054). At Visit 3, EGFR mutation status of 33/40 pts (83%) changed from positive to negative; 28 progressed, 5 died. Median PFS was 11 mo vs 6 mo for pts who remained EGFRm + (HR 1.25; 95% CI 0.47, 3.30; p = 0.6556).
Conclusions
In this analysis, there were no unexpected safety findings. There was no significant difference in PFS between pts with additional non-EGFR mutations vs those with EGFR-only mutations. Median PFS was almost twice as long in pts who became EGFR-mutation negative compared with those who remained EGFRm + (non-significant). This analysis suggests afatinib has clinical benefit for pts regardless of type of initial EGFR mutation.
Clinical trial identification
NCT01953913.
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Beth de Klerk of GeoMed, an Ashfield company, part of UDG Healthcare plc. The authors acknowledge Nick Xue, of Boehringer Ingelheim (China) Investment Co., and Agnieszka Cseh, of Boehringer Ingelheim RCV GmbH & Co. KG, for their support in the development of this abstract.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S. Meng: Full / Part-time employment: Boehringer Ingelheim. Y. Tian: Full / Part-time employment: Boehringer Ingelheim. D.C-L. Huang: Full / Part-time employment: Boehringer Ingelheim . Y-L. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly; Honoraria (self): MDS; Honoraria (self): BMS. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract